Analysis by the International Journal Nature

On July 6, Hanmi Pharmaceutical announced that it has been included in the global "Innovation Leaders" group in an analysis of pharmaceutical and biotech companies in Asia and other emerging markets, published by the internationally renowned academic journal Nature Reviews Drug Discovery.


This study comprehensively evaluated the innovation capabilities and research and development (R&D) productivity of pharmaceutical and biotech companies with annual sales of more than 500 million US dollars over the past 15 years, from 2010 to last year. The evaluation was based on their R&D investment ratio, clinical pipeline composition, and sales. The research was conducted on 45 major pharmaceutical and biotech companies in Asia, Latin America, and the Eastern Europe·Middle East·Africa (EEMEA) regions.


Hanmipharm R&D Center, Hwaseong, Gyeonggi Province. Hanmi Pharm

Hanmipharm R&D Center, Hwaseong, Gyeonggi Province. Hanmi Pharm

View original image

The paper classified the companies into three categories based on their R&D investment size and the proportion of innovative new drug pipelines: ▲Innovation Leaders ▲Emerging Innovators ▲Generic Leaders. Hanmi Pharmaceutical was included in the Innovation Leaders group, recognized for its R&D strategy focused on innovative new drugs and its high R&D productivity.


In particular, among the companies classified as Innovation Leaders over the past decade, Hanmi Pharmaceutical invested approximately 17 percent of its sales in R&D, which is the lowest level among its peers. Nevertheless, the company has been recognized for its innovation that exceeds its R&D investment scale, thanks to its pipeline centered on innovative new drugs and achievements such as global technology exports. The company highlighted the significance of this accomplishment.


The paper also introduced Hanmi Pharmaceutical as a leading example of a company that has successfully transformed itself into an innovation-driven organization by focusing on metabolic diseases and rare diseases as its core research areas. The authors assessed that "Innovation-leading pharmaceutical and biotech companies in Asia, especially in Korea and China, are preparing to grow into strong competitors for American and European firms based on their innovation strategies."



Choi Inyoung, Executive Vice President and Head of Future Growth at Hanmi Pharmaceutical, stated, "This evaluation is especially meaningful because it recognizes not just the size of our R&D investment, but also our R&D strategy and achievements centered around innovative new drugs from the perspective of R&D productivity. We will continue to do our best to deliver new treatment value to patients through differentiated innovative drug development and by strengthening our global R&D competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing